¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦70Â÷ ´ëÇѾฮÇÐȸ Ãß°èÇмú´ëȸ : 2018-11-01

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Á¦70Â÷ ´ëÇѾฮÇÐȸ Ãß°èÇмú´ëȸ : 2018-11-01
±³À°ÀÏÀÚ : 2018-11-01
±³À°Àå¼Ò : ±¤ÁÖ ¾Æ½Ã¾Æ¹®È­Àü´ç ±ØÀå3 ¿Ü 2°³·ë  
±³À°ÁÖÁ¦ : Á¦70Â÷ ´ëÇѾฮÇÐȸ Ãß°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇѾฮÇÐȸ
´ã´çÀÚ : À庴ȣ
¿¬¶ôó : 02-326-0370  
À̸ÞÀÏ : head@kosphar.org      
±³À°Á¾·ù : ¾à¸®ÇР     
Âü¼®¿¹»óÀοø : 250¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : ±¤ÁÖ±¤¿ª½Ã
±³À°½Ã°£ : 7 ½Ã°£ 30ºÐ  
¼¼ºÎ¼ö°­·á : 200,000¿ø      
ºñ°í ÆòÀÇ¿ø, Á¤È¸¿ø: 180,000¿øÁØȸ¿ø: 90,000¿øºñȸ¿ø: 200,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 11-01  12:00~13:00 µî·Ï  () 
±âŸ 11-01  13:00~13:10 °³È¸»ç  () 
±³À°½Ã°£ 11-01 ±ØÀå3 13:15~13:40 Cancer Genome and Chemical screening for precision oncology  ÀÌÁø±¸(¾ÆÁÖ´ë ÀÇ´ë) 
±³À°½Ã°£ 11-01 ±ØÀå3 13:40~14:05 Effects of dopamine receptor antagonists on cancer stem cell-like cells  ¹Ú¼º±Ô(°í·Á´ë ¾à´ë) 
±³À°½Ã°£ 11-01 ±ØÀå3 14:05~14:30 Studies on the inhibitory effects of a novel GnRHR ligand on prostate cancer and its mechanism  ±èÁö¿ø(¼­¿ï´ë ¾à´ë) 
±³À°½Ã°£ 11-01 °­ÀǽÇ1 13:15~13:40 TBA  ÀÌÁ¤È£(À»Áö´ë ÀÇ´ë) 
±³À°½Ã°£ 11-01 °­ÀǽÇ1 13:40~14:05 ½ºÆ®·¹½º¹ÝÀÀ¼º Àü»çÀÎÀÚ NPAS4ÀÇ Á¤½ÅÁúȯ Ä¡·á Ç¥ÀûÀ¸·ÎÀÇ ±Ô¸í  À±Àç¼®(ÃæºÏ´ë ¾à´ë) 
±³À°½Ã°£ 11-01 °­ÀǽÇ1 14:05~14:30 Evidence for Immunotherapy in Neuropsychiatric Disorders: Targeting Microglia  ±Ç¹Î¼ö(Â÷ÀÇ°ú ÀÇ´ë) 
±³À°½Ã°£ 11-01 ±ØÀå3 14:40~15:20 Unconventional Protein Secretion as a Target for New Drug Development  À̹α¸(¿¬¼¼´ë ÀÇ´ë) 
±³À°½Ã°£ 11-01 ±ØÀå3 15:20~16:00 Adipose Tissue Dysregulation and Insulin Resistance in Obesity  ±èÀç¹ü(¼­¿ï´ë »ý¸í°úÇкÎ) 
È޽Ġ11-01  16:00~16:15 ÈÞ½Ä ¹× À̵¿  () 
±³À°½Ã°£ 11-01 ±ØÀå3 16:15~16:50 The effect of arctigenin on MDA-MB-231 breast cancer cell death induced by doxorubicin  À̹α¸(µ¿±¹´ë ÀÇ´ë) 
±³À°½Ã°£ 11-01 ±ØÀå3 16:50~17:15 Development of antibody fragments for effective diagnostic and immunotherapy for cancer  Á¤ÈñÁø(È«ÀÍ´ë °ø´ë) 
±³À°½Ã°£ 11-01 ±ØÀå3 17:15~17:40 Study of erlotinib resistance in pancreatic cancer cells using multi-omics analysis  Àå¿øÁØ(°è¸í´ë ¾à´ë) 
±³À°½Ã°£ 11-01 ±ØÀå3 17:40~18:05 Development of lead compounds for blocking cancer metastasis by targeting the KITENIN complex  ¹èÁ¤¾Æ(Àü³²´ë ÀÇ´ë) 
±³À°½Ã°£ 11-01 °­ÀǽÇ1 16:15~16:50 MSK/ERK/CREB pathway: diverse roles in neurodegeneration and neurophysiology  ÃÖÀ±½Ä(°æ¼º´ë ¾à´ë) 
±³À°½Ã°£ 11-01 °­ÀǽÇ1 16:50~17:15 Targeting a novel catabolic regulator to alleviate osteoarthritis  ¾ç½Ã¿µ(¾ÆÁÖ´ë ÀÇ´ë) 
±³À°½Ã°£ 11-01 °­ÀǽÇ1 17:15~17:40 Prohibitin1 Regulates Interleukin-8 in Human Liver Cancers  ¾çÁø¿ø(¿ì¼®´ë ¾à´ë) 
±³À°½Ã°£ 11-01 °­ÀǽÇ1 17:40~18:05 Rescue of folding-defective membrane proteins by IRE¥á–mediated unconventional secretion  ¹Ú ÇÐ(¿¬¼¼´ë ÀÇ´ë) 
½Ä»ç 11-01  18:15~20:30 ¸¸Âù  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦70Â÷ ´ëÇѾฮÇÐȸ Ãß°èÇмú´ëȸ : 2018-11-01""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ºÎ»êµ¿ÀÇÀÇ·á¿ø ´ëÇѳúÁ¹ÁßÇÐȸ 2018³â 11¿ù ºÎ¿ï°æ³úÁ¹ÁßÇÐȸ Á¤±â¸ðÀÓ : 2018-11-01
´ÙÀ½±Û °­³²¼¼ºê¶õ½ºº´¿ø ôÃߺ´¿ø 11¿ù ¿ù·ÊÁý´ãȸ : 2018-11-01
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21062 ¼­¿ï (¿Â¶óÀÎ)¹ÙÀÌ¿Àºòµ¥ÀÌÅÍÀÇ È°¿ë°ú ÃֽŠ¿ªÇÐ ¼³°è ¹× ±â°èÇнÀ(4ÀÏÂ÷) : 2024-07-04 0 96 2024-06-18
21061 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀçÅÃÀÇ·á ȯÀÚ Áø·áÀÇ ½ÇÁ¦ : 2024-07-04 0 49 2024-06-18
21060 ¿ï»ê ´ëÇÑ»êºÎÀΰúÀÇ»çȸ ¿ï»êÁöȸ ¿¬¼ö±³À°(¿ù°æÅë, µ¥³ë¼ö¹ä Áß´Ü ÈÄ ¹Ýµ¿°ñÀýÀÇ ¿¹¹æ) : 2024-07-04 0 75 2024-06-18
21059 ¼­¿ï (¿Â¶óÀÎ)¹ÙÀÌ¿Àºòµ¥ÀÌÅÍÀÇ È°¿ë°ú ÃֽŠ¿ªÇÐ ¼³°è ¹× ±â°èÇнÀ(3ÀÏÂ÷) : 2024-07-03 0 17 2024-06-18
21058 °æ±â 2024³â ÆòÅýÃÀÇ»çȸ ÇÏ°èÇмú´ëȸ : 2024-07-02 0 96 2024-06-18
21057 ¼­¿ï ¿Â¶óÀÎ)¹ÙÀÌ¿Àºòµ¥ÀÌÅÍÀÇ È°¿ë°ú ÃֽŠ¿ªÇÐ ¼³°è ¹× ±â°èÇнÀ(2ÀÏÂ÷) : 2024-07-02 0 59 2024-06-18
21056 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-01 0 42 2024-06-18
21055 ¼­¿ï (¿Â¶óÀÎ)¹ÙÀÌ¿Àºòµ¥ÀÌÅÍÀÇ È°¿ë°ú ÃֽŠ¿ªÇÐ ¼³°è ¹× ±â°èÇнÀ(1ÀÏÂ÷) : 2024-07-01 0 39 2024-06-18
21054 ÃæºÏ ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ Understanding Current Community Mental Health and Emotional Disorders in ASD : 2024-07-01 0 69 2024-06-18
21053 ¼­¿ï (¿Â¶óÀÎ) 2024³âµµ °³¿øÀÇ ½ÉÆ÷Áö¾ö : 2024-06-30 0 57 2024-06-18
21052 °æ±â ´ëÇÑÁ¤ÇüÅëÁõÀÇÇÐȸ - Á¦2ȸ CHAMS °³¿øÀÇ ½ÉÆ÷Áö¾ö : 2024-06-30 0 63 2024-06-18
21051 ¼­¿ï 2024³â ´ëÇÑ°¡Á¤ÀÇÇÐȸ ¼­¿ïÁöȸ Çϰ迬¼ö°­Á : 2024-06-30 0 78 2024-06-18
21050 ºÎ»ê 2024³â ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ºÎ¿ï°æÁöȸ ¿¬¼ö°­Á : 2024-06-30 0 35 2024-06-18
21049 ¼­¿ï Á¦26Â÷ ´ëÇѾƵ¿º´¿øÇùȸ Ãá°èÇмú´ëȸ : 2024-06-30 0 26 2024-06-18
21048 Ãæ³² 2024 ÀÌ°úÇÐ ¿¬±¸¼¼¹Ì³ª : 2024-06-29 0 26 2024-06-18
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷